The obesity drug revolution

Inside the obesity drug revolution

Known as GLP-1 agonists, new drugs could change how doctors treat obesity and, possibly, how the condition is more broadly understood. They could also raise healthcare spending substantially, posing a problem for insurers looking to control costs.

INCLUDED IN THIS TRENDLINE

Novo obesity drug protects heart health in large trial
New kind of obesity drug sets ‘high bar’ in mid-stage study
Lilly’s fortunes rise on back-to-back success for obesity, Alzheimer’s drugs

Unlock the free Trendline by BioPharma Dive

First Name*

Last Name*

Email*

Company Name*

Company Type *

Job Title*

Yes, I'd like to sign up for the BioPharma Dive newsletter. You can unsubscribe at any time.

By completing this form, you accept the Terms of Use and Privacy PolicyYou also agree to having your information shared with our sponsor, GoodRx.*